

CV Date

01/02/2024

Part A. PERSONAL INFORMATION

First Name *	Eduardo		
Family Name *	Pérez Gómez		
Sex *	Not Specified	Date of Birth *	
ID number Social Security, Passport *		Phone Number *	
URL Web	http://cannabinoidsignalling.com		
Email Address			
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0003-0160-5565	
	Researcher ID	F-5906-2015	
	Scopus Author ID	8609069800	

* Mandatory

A.1. Current position

Job Title	Profesor Titular de Universidad		
Starting date	2020		
Institution	Universidad Complutense de Madrid		
Department / Centre	Bioquímica y Biología Molecular / CC Químicas		
Country	Spain	Phone Number	(34) 913944668
Keywords	Molecular mechanism of disease; Laboratoy animals; Cell culture; Molecular, cellular and genetic biology		

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2018 - 2020	Profesor Contratado Doctor / Universidad Complutense de Madrid
2015 - 2018	Investigador contratado / Universidad Complutense de Madrid
2010 - 2015	Investigador contratado (Asociación Española Contra el Cáncer) / Asociación Española Contra el Cáncer
2012 - 2012	Estancia posdoctoral / University Hospital of Schleswig-Holstein (UK-SH)
2009 - 2009	Investigador Contratado / Universidad Complutense de Madrid
2007 - 2009	Investigador Contratado / Consejo Superior de Investigaciones Científicas
2003 - 2007	Becario predoctoral -FPI/CAM / Consejo Superior de Investigaciones Científicas
2001 - 2002	Becario de Colaboración / Universidad Autónoma de Madrid

A.3. Education

Degree/Master/PhD	University / Country	Year
Bioquímica, Biología Molecular y Biomedicina (extraordinary doctorate award)	Universidad Autónoma de Madrid / Spain	2007
Licenciado en Bioquímica	Universidad Autónoma de Madrid	2002

A.4. General quality indicators of scientific production

Six-year terms of research: 3 (Last, 2015-2020)

Doctoral theses supervised: 2 and 2 ongoing.

Director of 7 Master's Thesis and 5 Final Degree Projects.

Publications in Q1: 33, 19 in the last 10 years.

Publications in Q1 with leadership: 12 (9 in D1)

Total citations: ~1500 (WOS)

Total international patents: 2

Index h=20 (WOS)

Reviewer for the scientific journals Cell death and disease, Oncogene, Int J Cancer, Scientific Reports, Cancers, Oncotarget, Journal of Translational Medicine, etc.

Reviewer for the National Agency for Evaluation and Prospective (ANEP), Auckland Medical Research Foundation (New Zealand) and Technical collaborator of the entity for the certification of Research and Development or Technological Innovation (R+D+i) projects (ACERTA I+D+i).

Part B. CV SUMMARY

Eduardo Pérez Gómez studied Biochemistry at the Autonomous University of Madrid (UAM), where he graduated in 2002 and obtained his PhD in 2007 (with Extraordinary PhD Award) working at the Instituto de Investigaciones Biomédicas "Alberto Sols" under the direction of Professor Miguel Quintanilla. She did postdoctoral stays at the Schleswig-Holstein University Hospital, UKSH (Germany) and at the Spanish National Cancer Research Centre, CNIO (Madrid). In 2010 he was eligible for the Juan de la Cierva programme and the postdoctoral contract programme of the Spanish Association Against Cancer (AECC). Since 2020 he is Full Professor in the Department of Biochemistry and Molecular Biology at the Complutense University of Madrid, UCM. His research aims to contribute to the understanding of the molecular mechanisms that control the development of the mammary gland as well as the generation and progression of breast cancer, especially in the context of the endocannabinoid system (see <http://cannabinoidsignalling.com>). This work has allowed the characterisation of new mechanisms of action and effects mediated by this cell-cell communication system, as well as suggesting new pathophysiological and therapeutic implications derived from it. In 2019 he obtained the I3 certificate from the Ministry of Science. His research work has resulted in 31 scientific publications published in prestigious journals such as Nature Communications, PNAS USA, J Natl Cancer Inst, Molecular Cancer, Cancer Res or Oncogene, among others, (h WOS index = 20), 15 research projects, 7 of them as Principal Investigator and 2 international patents. He has supervised 2 doctoral theses, 2 in progress, 7 Master's theses, 5 Bachelor's theses and collaborates regularly as a reviewer in various research agencies.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Tundidor, Isabel; Seijo-Vila, Marta; Blasco-Benito, Sandra; et al; (10/10) Perez-Gomez, Eduardo (AC). 2024. Fatty acid amide hydrolase drives adult mammary gland development by promoting luminal cell differentiation. CELL DEATH DISCOVERY. SPRINGERNATURE. 10-1. ISSN 2058-7716. WOS (0) <https://doi.org/10.1038/s41420-023-01788-1>
- 2 **Scientific paper.** Isabel Tundidor; Marta Seijo-Vila; Sandra Blasco-Benito; et al; (25/25) Eduardo Pérez-Gómez (AC). 2023. Identification of fatty acid amide hydrolase as a new metastasis suppressor in breast cancer. Nature Communications. Springer Nature. 14-3130, pp.1-14. ISSN 2041-1723.
- 3 **Scientific paper.** Pinto-Diez, C.; Ferreras-Martin, R; Carrion-Marchante, R; et al; Martin, M. E.; (12/17) Perez-Gomez, E.2022. An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer. MOLECULAR THERAPY-NUCLEIC ACIDS. CELL PRESS. pp.553-568. ISSN 2162-2531. WOS (2) <https://doi.org/10.1016/j.omtn.2022.11.009>

- 4 Scientific paper.** Marín-Rubio, JL; Vela Martin, Laura; Gudgeon, Jack; et al; Villa-Morales, Maria; (4/10) Perez-Gomez, Eduardo. 2022. A Dual Role for FADD in Human Precursor T-Cell Neoplasms. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 23-23. ISSN 1422-0067. WOS (2) <https://doi.org/10.3390/ijms232315157>
- 5 Scientific paper.** Marín-Rubio JL; (2/4) Pérez-Gómez E; Fernández-Piqueras J; Villa-Morales M. 2019. S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma. Carcinogenesis. 40-10, pp.1260-1268. ISSN 0143-3334. WOS (13) <https://doi.org/10.1093/carcin/bgz041>
- 6 Scientific paper.** Blasco-Benito S; Moreno E; Seijo-Vila M; et al; Sánchez C; (24/25) Perez-Gomez E (AC). 2019. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America. National Academy of Sciences. 116-9, pp.3863-3872. ISSN 0027-8424. WOS (32) <https://doi.org/10.1073/pnas.1815034116>
- 7 Scientific paper.** Blasco-Benito, Sandra; Seijo-Vila, Marta; Caro-Villalobos, Miriam; et al; Sanchez, Cristina; (10/12) Perez-Gomez, Eduardo. 2018. Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. BIOCHEMICAL PHARMACOLOGY. PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND. 157, pp.285-293. ISSN 0006-2952. WOS (72) <https://doi.org/10.1016/j.bcp.2018.06.025>
- 8 Scientific paper.** Lucia-Tran J; Tulkki V; Smith S; et al; Coleman N; (9/13) Pérez-Gómez E. 2016. Over-expression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and increased metastasis. British Journal of Cancer. nature publishing group. 115-2, pp.212-222. ISSN 0007-0920. WOS (32) <https://doi.org/10.1038/bjc.2016.199>
- 9 Scientific paper.** Andradeas C; Blasco-Benito S; Castillo-Lluva S; et al; Sánchez C; (23/24) Perez-Gomez E (AC). 2016. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget. Impact Journals, LLC. 7-30, pp.47565-47575 (AUTOR DE CORRESPONDENCIA). ISSN 1949-2553. WOS (34) <https://doi.org/10.18632/oncotarget.10206>
- 10 Scientific paper.** (1/32) Perez-Gomez E (AC); Andradeas C; Blasco-Benito S; et al; Sánchez C. 2015. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. Journal of the National Cancer Institute. Oxford University Press. 107-6, pp.10.1093/jnci/djv077 (AUTOR DE CORRESPONDENCIA). ISSN 0027-8874. WOS (81) <https://doi.org/10.1093/jnci/djv077>
- 11 Scientific paper.** Marín-Ramos NI; Dulce-Alonso D; Ortega-Gutiérrez S; et al; López-Rodríguez ML; (9/15) Perez-Gomez E. 2015. New inhibitors of angiogenesis with antitumoral activity in vivo. Journal of Medicinal Chemistry. ACS publications. 58-9, pp.3757-3766. ISSN 0022-2623. WOS (16) <https://doi.org/10.1021/jm5019252>
- 12 Scientific paper.** Salazar M; Lorente M; García-Taboada E; et al; Velasco; (4/22) Pérez Gómez E. 2015. The pseudokinase tribbles homologue-3 supresses tumorigenesis by controling the mtorc2/akt/foxo axis. Molecular & Cellular Oncology. tandfonline.com. 2-2, pp.e980134. ISSN 1350-9047. WOS (2) <https://doi.org/10.4161/23723556.2014.980134>
- 13 Scientific paper.** Tomé-Amat J; Olombrada M; de la Herrán JR; et al; Lacadena J; (4/10) Pérez-Gómez E. 2015. Efficient in vivo antitumor effect of a colorectal cancer specific immunotoxin based on ribotoxin ?-sarcin. Springerplus. Springer. 4-168, pp.doi:10.1186/s40064-015-0943-5. ISSN 2193-1801. WOS (22) <https://doi.org/10.1186/s40064-015-0943-5>
- 14 Scientific paper.** Quintanilla M; Del Castillo G; Sánchez-Blanco E; et al; Bernabéu C; (7/9) Pérez-Gómez E. 2015. A suppressor role for soluble endoglin in cancer. Cancer Cell & Microenvironment. Smart Science & Technology LLC, USA.. 2-2, pp.e706. doi: 10.14800/ccm.706. ISSN 1460-2180. <https://doi.org/10.14800/ccm.706>

- 15 Scientific paper.** Del Castillo G; Sánchez-Blanco E; Martín-Villar E; et al; Quintanilla M; (6/9) Pérez-Gómez E. 2015. Soluble endoglin antagonizes Met signaling in spindle carcinoma cells. *Carcinogenesis*. Oxford Journal. 36-2, pp.212-222. ISSN 1460-2180. WOS (6) <https://doi.org/10.1093/carcin/bgu240>
- 16 Scientific paper.** Salazar M; Lorente M; García-Taboada E; et al; Velasco; (4/22) Pérez Gómez E. 2015. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. *Cell Death & Differentiation*. nature publishing group. 22-1, pp.131-144. ISSN 1350-9047. WOS (65) <https://doi.org/10.1038/cdd.2014.133>
- 17 Scientific paper.** Moreno E; Andradas C; Medrano M; et al; Sánchez C; (5/12) Pérez-Gómez E. 2014. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. *The Journal of Biological Chemistry*. American Society for Biochemistry and Molecular Biology. 289-32, pp.21960-21972. ISSN 0021-9258. WOS (72) <https://doi.org/10.1074/jbc.M114.561761>
- 18 Scientific paper.** (1/9) Pérez-Gómez E; Jerkic M; Prieto M; et al; López-Novoa JM. 2014. Impaired wound repair in adult endoglin heterozygous mice associated with lower NO bioavailability. *Journal of Investigative Dermatology*. NATURE PUBLISHING GROUP. 134-1, pp.247-255. ISSN 0022-202X. WOS (12) <https://doi.org/10.1038/jid.2013.263>
- 19 Scientific paper.** (1/7) Pérez-Gómez E; Andradas C; Flores JM; Quintanilla M; Paramio JM; Guzmán M; Sánchez. 2013. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. *Oncogene*. NATURE PUBLISHING GROUP. 32-20, pp.2534-2542. ISSN 0950-9232. WOS (64) <https://doi.org/10.1038/onc.2012.278>
- 20 Scientific paper.** Caffarel MM; Andradas C; (3/5) Pérez-Gómez E; Guzmán M; Sánchez C. 2012. Cannabinoids: a new hope for breast cancer therapy?. *Cancer Treatment Reviews*. ELSEVIER SCI LTD. 38-7, pp.911-918. ISSN 0305-7372. SCOPUS (28) <https://doi.org/10.1016/j.ctrv.2012.06.005>
- 21 Scientific paper.** Andradas C; Caffarel MM; (3/8) Pérez-Gómez E; Salazar M; Lorente M; Velasco G; Gúzman M; Sánchez C. 2011. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. *Oncogene*. NATURE PUBLISHING GROUP. 30-2, pp.245-252. ISSN 0950-9232. WOS (53) <https://doi.org/10.1038/onc.2010.402>
- 22 Scientific paper.** (1/8) Pérez-Gómez E; Santibanez JF; Fernandez-L A; Carnero A; Malumbres M; Vary C.P.H; Quintanilla M; Bernabéu C. 2010. The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. *Carcinogenesis*. Oxford Journal. 31-12, pp.2145-2154. ISSN 1460-2180. WOS (11) <https://doi.org/10.1093/carcin/bgq199>
- 23 Scientific paper.** Martin-Villar E; Fernández-Muñoz B; Parsons M; Yurrita MM; Megías D; (6/8) Pérez-Gómez E; Jones GE; Quintanilla M. 2010. Podoplanin Associates with CD44 to Promote Directional Cell Migration. *Molecular Biology of the Cell*. The American Society for Cell Biology.. 21-24, pp.245-252. ISSN 1059-1524. SCOPUS (13)
- 24 Scientific paper.** (1/6) Pérez-Gómez E; del Castillo G; Santibáñez JF; López-Novoa JM; Bernabéu C; Quintanilla M. 2010. The role of the TGFbeta co-receptor endoglin in cancer. *THE SCIENTIFIC WORLD JOURNAL*. THESCIENTIFICWORLD LTD. 10, pp.2367-2384. ISSN 1537-744X. SCOPUS (14)
- 25 Scientific paper.** Caffarel MM; Andradas C; Mira E; et al; Sánchez C; (4/12) Pérez-Gómez E. 2010. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Molecular Cancer*. BioMed Central. 9-196. ISSN 1476-4598. SCOPUS (14)
- 26 Scientific paper.** Blanco FJ; Grande MT; Langa C; et al; Bernabéu C; (7/10) Pérez-Gómez E. 2008. S-Endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. *Circulation Research*. American Heart Association. 103-12, pp.1383-1392. ISSN 0009-7330. SCOPUS (37)
- 27 Scientific paper.** Peinado H; Moreno-Bueno G; Hardisson D; et al; Cano A; (4/11) Pérez-Gómez E. 2008. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. *Cancer Research*. American Association for Cancer Research. 68-12, pp.4541-4550. ISSN 0008-5472. SCOPUS (46)

- 28 Scientific paper.** (1/8) Pérez-Gómez E; Villa-Morales M; Santos J; Fernández-Piqueras J; Gamallo C; Dotor J; Bernabéu C; Quintanilla M. 2007. A role for endoglin as a suppressor of malignancy during skin carcinogenesis. *Cancer Research. American Association for Cancer Research.* 67-21, pp.10268-10277. ISSN 0008-5472. SCOPUS (26) <https://doi.org/10.1158/0008-5472.CAN-07-1348>
- 29 Scientific paper.** Villa-Morales M; Santos J; (3/5) Pérez-Gómez E; Quintanilla M; Fernández-Piqueras J. 2007. A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas. *Cancer Research. American Association for Cancer Research.* 67-11, pp.5107-5116. ISSN 0008-5472. SCOPUS (7)
- 30 Scientific paper.** (1/8) Pérez-Gómez E; Eleno N; López-Novoa JM; Ramírez JR; Velasco B; Letarte M; Bernabéu C; Quintanilla M. 2005. Characterization of murine S-endoglin isoform and its effect on tumor development. *Oncogene. NATURE PUBLISHING GROUP.* 24-27, pp.4450-4461. ISSN 0950-9232. WOS (53) <https://doi.org/10.1038/sj.onc.1208644>
- 31 Scientific paper.** Quintanilla M; Ramírez JR; (3/8) Pérez-Gómez E; Romero D; Velasco B; Letarte M; López-Novoa JM; Bernabéu C. 2003. Expresión de la TGFbeta coreceptor endoglin en queratinocitos epidermicos y su doble papel en el desarrollo de carcinogenesis. *Oncogene. NATURE PUBLISHING GROUP.* 4-22, pp.5976-5985. ISSN 0950-9232. SCOPUS (21)
- 32 Scientific paper.** Isabel Tundidor; Marta Seijo-Vila; Sandra Blasco-Benito; et al; (9/9) Eduardo Pérez-Gómez (AC). 2023. Fatty acid amide hydrolase drives luminal cell differentiation in the adult mammary gland. *bioRxiv (PrePrint).* <https://doi.org/10.1101/2023.04.03.535417>
- 33 Scientific paper.** María Villa-Morales; Laura Pérez-Gómez; (3/6) Eduardo Pérez-Gómez; Pilar López-Nieva; Pablo Fernández-Navarro; Javier Santos. 2023. Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia. *International Journal of Molecular Sciences. MDPI.* 24-12, pp.10350-10360. ISSN 1422-0067. <https://doi.org/10.3390/ijms241210350>
- 34 Scientific paper.** Carlos Costas-Insua; Marta Seijo-Vila; Cristina Blázquez; et al; Manuel Guzmán; (7/10) Eduardo Pérez-Gómez. 2023. Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling. *Cancers. MDPI.* 15-9, pp.2439-2442. ISSN 2072-6694. <https://doi.org/10.3390/cancers15092439>.
- 35 Scientific paper.** Perez-Gomez, E.; Andradas, C.; Quintanilla, M.; Flores, J. M.; Paramio, J.; Guzman, M.; Sanchez, C. 2012. A Role for GPR55 in Multistage Mouse Skin Carcinogenesis. *EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.* 48-5, pp.S163-S163. ISSN 0959-8049.
- 36 Scientific paper.** (1/7) Pérez-Gómez E; Andradas C; Flores JM; Quintanilla M; Paramio JM; Guzmán M; Sánchez. 2012. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. *European Journal of Cancer. Elsevier.* 48-S5, pp.163-163. ISSN 0959-8049. SCOPUS (0)
- 37 Book chapter.** Andradas C; Caffarel MM; (3/5) Pérez-Gómez E; Guzmán M; Sánchez C. 2012. The role of GPR55 in cancer. *CANNABINOIDS: Actions at Non-CB1/CB2 Cannabinoid Receptors.* Springer. ISBN 978-3-540-44328-5.
- 38 Book chapter.** Quintanilla M; (2/5) Pérez-Gómez E; Romero D; Pons M; Renart J. 2004. TGFbeta pathway and cancerogenesis of epithelial skin tumours. Molecular mechanisms of basal cell and squamous cell carcinomas. *Landes Bioscience and Springer Science.* pp.81-93. ISBN 978-0-387-26046-4.
- 39 Book chapter.** Quintanilla M; Frontelo P; Pons M; Romero D; (5/7) Pérez Gómez E; Gamallo C; Iglesias M. 2003. TGFbeta signaling and epidermal carcinogenesis. *Recent Research Development in Cellular Biochemistry.* Transworld Research Network. pp.151-160. ISBN 81-7895-080-4.

- 40 Scientific-technical report.** (1/8) Pérez-Gómez E; Santibanez JF; Fernandez-L A; Carnero A; Malumbres M; Vary C.P.H; Quintanilla M; Bernabéu C. 2010. The TGFbeta co-receptor endoglin modulates the expression and transforming potential of H-Ras. European Journal of Cancer Supplements. PERGAMON-ELSEVIER SCIENCE LTD. 8-5, pp.184-184. ISSN 1359-6349.
- 41 Scientific-technical report.** Andradas C; Caffarel MM; Salazar M; (4/8) Pérez-Gómez E; Lorente M; Velasco G; Gúzman M; Sánchez C. 2010. The putative cannabinoid receptor GPR55 participates in the control of cancer cell proliferation. European Journal of Cancer Supplements. PERGAMON-ELSEVIER SCIENCE LTD. 8-5, pp.91-91. ISSN 1359-6349.
- 42 Scientific-technical report.** (1/8) Pérez-Gómez E; Villa-Morales M; Santos J; Fernández-Piqueras J; Gamallo C; Dotor J; Bernabéu C; Quintanilla M. 2009. A role for auxiliary TGF-beta receptor endoglin as a modulator of tumour progression. European Journal of Cancer Supplements. PERGAMON-ELSEVIER SCIENCE LTD. 7-2, pp.89-90. ISSN 1359-6349.
- 43 Scientific-technical report.** Villa-Morales M; Santos J; (3/5) Pérez-Gómez E; Quintanilla M; Fernández-Piqueras J. 2007. A role for the Fas/FasL system in modulating genetic susceptibility to Tcell lymphoblastic lymphomas. European Journal of Cancer Supplements. PERGAMON-ELSEVIER SCIENCE LTD. 5-4, pp.70-71. ISSN 0008-5472. SCOPUS (6)
- 44 SECUENCIAS REGISTRADAS EN GenBank.** Pérez-Gómez E; Quintanilla M. 2005. Mus musculus S-endoglin (Eng) mRNA, complete cds, alternatively spliced.pubmed.
- C.3. Research projects and contracts**
- 1 Project.** PI23/00765, El sistema endocannabinoide en el microambiente tumoral: papel en la progresión y respuesta a inmunoterapia en cáncer de mama. Instituto de Salud Carlos III. Eduardo Pérez Gómez. (Hospital 12 de Octubre / Universidad Complutense de Madrid). 01/01/2024-31/12/2026. 265.000 €. Principal investigator.
 - 2 Project.** PI20/00590, Potencial del sistema endocannabinoide como diana terapéutica y herramienta de cribado en cáncer de mama. Instituto de Salud Carlos III. Eduardo Pérez Gómez. (Hospital 12 de Octubre / Universidad Complutense de Madrid). 01/01/2021-31/12/2023. 220.220 €. Principal investigator.
 - 3 Project.** i12-AY220114-1, Los heterómeros HER2-CB2 como diana terapéutica y herramienta pronóstico/predictiva en cáncer de mama HER2 positivo. Programa de fomento de la I+D+i en el i+12.INVESTIGA12. (Hospital Universitario 12 de Octubre). 01/01/2022-31/12/2022. 35.000 €. Principal investigator.
 - 4 Project.** i12-AY201228-1, Los heterómeros HER2-CB2 como diana terapéutica y herramienta pronóstico/predictiva en cáncer de mama HER2 positivo. Programa de fomento de la I+D+i en el i+12.INVESTIGA12. (Hospital Universitario 12 de Octubre). 01/01/2021-31/12/2021. 35.000 €. Principal investigator.
 - 5 Project.** PI17/00041, Los heterómeros HER2-CB2 como diana terapéutica y herramienta pronóstico/predictiva en cáncer de mama HER2 positivo. Instituto de Salud Carlos III. Eduardo Pérez Gómez. (Hospital 12 de Octubre / Universidad Complutense de Madrid). 01/01/2018-31/12/2020. 130.000 €. Principal investigator.
 - 6 Project.** Comparación de la eficacia antitumoral de cannabinoides aislados frente a preparados completos de la planta. Fundación Científica Asociación Española Contra el Cáncer (FCAECC). Eduardo Pérez Gómez. (UCM/i+12). 01/10/2017-30/09/2019. 20.000 €. Principal investigator.
 - 7 Project.** PI14/01101, El sistema endocannabinoide en cáncer de mama HER2+: papel en la generación y progresión tumorales, y potencial como diana terapéutica y marcador pronóstico.. Ministerio de Sanidad y Consumo. Eduardo Perez Gomez. (Universidad Complutense de Madrid-Fundación Doce de Octubre). 01/01/2015-31/12/2017. 140.000 €. Principal investigator.
 - 8 Project.** S2010/BMD-2308, Neurofarmacología del sistema endocannabinoide: del laboratorio a la clínica. Comunidad de Madrid (programa de actividades de i+d en biociencias). Manuel Guzmán. (Universidad Complutense de Madrid). 01/01/2012-31/12/2015. 922.975 €. Team member.

- 9 Project.** Análisis del efecto antitumoral de la combinación de terapias anti-Her2 y cannabinoides en cáncer de mama Her2 positivo. Fundación Sandra Ibarra. Cristina Sánchez. (Universidad Complutense de Madrid-Fundación Doce de Octubre). 01/01/2014-2015. 20.000 €. Team member.
- 10 Project.** Análisis del efecto anti-tumoral de la combinación de cannabinoides y terapia anti-Her2 en mujeres con cáncer de mama HER2 positivo. Fundación Mutua Madrileña. Luis Manso. (Universidad Complutense de Madrid-Fundación Doce de Octubre). 01/01/2013-2015. 27.000 €. Team member.
- 11 Project.** PI11/00295, Papel del receptor huérfano GPR55 en la patogénesis del cáncer: potencial como nuevo biomarcador y diana terapéutica en oncología. FIS MICINN-ISCIII. Cristina Sánchez. (Universidad Complutense de Madrid). 01/01/2012-01/01/2014. 135.000 €. Team member. Investigador Contratado
- 12 Project.** AT 2009-0016, Involvement of the orphan receptor GPR55 in cannabinoid antitumoral action. MICINN (Acciones Integradas). Cristina Sánchez. (Universidad Complutense de Madrid). 01/01/2009-31/12/2011. 12.000 €. Team member.
- 13 Project.** SAF2007-63821, Bases moleculares de la función de endoglina y podoplanina/antígeno PA2.26 en la transición epitelio-mesénquima y en la progresión maligna de carcinomas. (MCYT: SAF2007-63821). SAF. Miguel Quintanilla. (Instituto de Investigaciones Biomédicas Alberto Sols). 01/01/2007-31/12/2009. 350.000 €. Team member.
- 14 Project.** SAF2004-04902, Mecanismos implicados en la progresión maligna de carcinomas epidermoides. Estudios sobre endoglina y el antígeno PA2.26. (MCYT: SAF2004-04902). Plan Nacional. Miguel Quintanilla. (Instituto de Investigaciones Biomédicas Alberto Sols). 01/01/2004-31/12/2006. 160.000 €. Team member.
- 15 Project.** Nodo del IIB (Instituto de Investigaciones Biomédicas), Mecanismos de transformación neoplásica, invasión y metástasis.. Redes Temáticas de Investigación Cooperativa de Centros de Cáncer. Amparo Cano. (Instituto de Investigaciones Biomédicas Alberto Sols). 01/01/2003-31/12/2005. 200.000 €. Team member.
- 16 Project.** SAF2001-2361, Mecanismos implicados en la transición epitelio-mesénquima durante la progresión maligna de carcinomas.. Plan Nacional. Miguel Quintanilla. (Instituto de Investigaciones Biomédicas Alberto Sols). 01/01/2001-31/12/2003. 90.000 €. Team member.
- 17 Project.** POTENCIAL DEL SISTEMA ENDOCANNABINOIDE COMO DIANA TERAPEUTICA Y HERRAMIENTA DE CRIBADO EN CANCER DE MAMA. Instituto de Salud Carlos III. (INSTITUTO DE INVESTIGACION HOSPITAL 12 DE OCTUBRE (i+12)).
- 18 Contract.** Anti-tumour effect of cannabinoids in HER2+ and triple negative breast cancer (artículo 83) Zelda Therapeutics Pty Ltd. Cristina Sánchez García. (Zelda Therapeutics Pty Ltd). 01/03/2016-01/03/2020. 290.000 €.
- 19 Contract.** Antitumoural effect of cannabinoids in breast and other cancer (artículo 83) GW Pharma Ltd. Cristina Sánchez García. (GW Pharma Ltd). 01/10/2009-01/10/2015. 350.000 €.

C.4. Activities of technology / knowledge transfer and results exploitation

- 1 Patent of invention.** Cristina SÁNCHEZ GARCIA; Sandra BLASCO BENITO; Eduardo PÉREZ GÓMEZ. WO/2018/071986. PROGNOSTIC METHOD AND KITS USEFUL IN SAID METHOD PCT/AU2017/051146 Australia. 26/04/2018. ZELDA THERAPEUTICS OPERATIONS PTY LTD.
- 2 Patent of invention.** Cristina Sánchez; Manuel Guzmán; Stephen Wright; Colin Stott; María Muñoz Caffarel; Clara Andradas; Eduardo Pérez Gómez. 12780523.2-1464. Phytocannabinoids for use in the treatment of breast cancer US/21.10.11/USP201161550069 United States of America. 2014. GW Pharmaceuticals. GW Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization, Inc.

- 3 Patent of invention.** Cristina Sánchez; Manuel Guzmán; Stephen Wright; Colin Stott; María Muñoz Caffarel; Clara Andradas; Eduardo Pérez Gómez. US2014314757-A1. Use of oral presentation of tetrahydrocannabinol and/or a cannabidiol for treating aggressive breast cancer, or for treating, preventing or reducing the risk of a cancer metastasis. US2014314757-A1 United States of America. 2014. GW Pharmaceuticals. GW Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization, Inc.